Omeros Corp is a high-risk pharmaceutical company in the United States dedicated to developing innovative therapies for immunologic disorders, cancers, and other conditions. Their lead drug candidate, narsoplimab (OMS721), focuses on complement-mediated diseases and is currently in clinical trials for various conditions. With an ESG score of 36.8, Omeros Corp is committed to sustainable practices in the healthcare industry.